慢性胰腺炎和 3C 型糖尿病

王 宏亮¹, 林 春花¹, 金 娜¹, 易 庆华¹, 徐 玉善²
1、昆明市官渡区人民医院
2、昆明医科大学第一附属医院

摘要

3c 型糖尿病继发于原发性胰腺疾病损害之后。与 1 型或 2 型糖尿病的治疗相比，T3cDM 常伴有外分泌功能不全导
致的消化不良和营养不良。而慢性胰腺炎是 3c 型糖尿病的主要原因，继发于慢性胰腺炎的糖尿病的患病率和临床重要性被
低估。导致未能实施适当的治疗，本文结合近期发现与对其病因、临床表现、治疗和预后与其他类型糖尿病的区别等方面进
行简述和回顾，以加深医疗中疾病的重视程度，提升治疗水平。

关键词

3c 型糖尿病；慢性胰腺炎；胰腺外分泌功能不足

参考

[1] Hao L, Zeng XP, Xin L, et al. Incidence of and risk

factors for pancreatic cancer in chronic pancreatitis: A cohort of

1656 patients. Dig Liver Dis. 2017;49(11):1249-1256. [2] Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J. Chronic pancreatitis. Lan- cet 2020;396:499-512. Aune, D., et al., Tobacco smoking and the risk of

pancreatitis:A systematic review and meta-analysis of prospective

studies.Pancreatology, 2019. [3] Levy P, et al. Epidemiology of chronic pancreatitis: burden of the disease and consequences. United Eur Gastroenterol

J. 2014;2(5):345–54. [4] Domínguez ­ Muñoz JE, Lucendo A, Carballo LF, Iglesias ­García J, Tenías JM. A Spanish multicenter study to

estimate the prevalence and incidence of chronic pancreatitis and

its complications. Rev Esp Enferm Dig 2014; 106: 239–45. [5] Hirota M, Shimosegawa T, Masamune A, et al. The

seventh nationwide epidemiological survey for chronic pancreatitis

in Japan: clinicalsignificance ofsmoking habit in Japanese patients. Pancreatology 2014; 14: 490–96. [6] Peery AF, Crockett SD, Murphy CC, et al. Burden and

cost of gastrointestinal, liver, and pancreatic diseases in the United

States: update 2018. Gastroenterology 2019; 156: 254–72.e11. [7] Wang W, Guo Y, Liao Z, Zou DW, Jin ZD, Zou DJ, Jin

G, Hu XG, Li ZS . Occurrence of and risk factors for diabe- tes mellitus in Chinese patients with chronic pancreatitis. Pancreas 2011; 40: 206-212. [8] Rebours V, Boutron-Ruault MC, Schnee M, Férec C, Le Maréchal C, Hentic O, Maire F, Hammel P, Ruszniewski P, Lévy P. The natural history of hereditary pancreatitis: a national series. Gut

2009; 58: 97-103 . [9] 中国医师协会胰腺病专业委员会慢性胰腺炎专委会. 慢 性 胰 腺 炎 诊 治 指 南 (2018 年 , 广 州 )[J]. 中 华 消 化 杂

志,2018,38(11):739-746. [10] Mayerle J, Sendler M, Hegyi E, Beyer G, Lerch MM, Sahin-Toth M. Genetics, cell biology, and pathophysiology of

pancreatitis. Gastroenterology 2019; 156: 1951–68.e1. [11] LaRusch J, Lozano ­ Leon A, Stello K, et al. The

common chymotrypsinogen C ( CTRC) variant G60G (c.180T)

increases risk of chronic pancreatitis but not recurrent acute pancreatitis in a North American population. Clin Transl

Gastroenterol 2015; 6: e68. [12] Jalaly NY, Moran RA, Fargahi F, et al.An evaluation of

factors associated with pathogenic PRSS1, SPINK1, CTFR, and/or CTRC genetic variants in patients with idiopathic pancreatitis. Am

JGastroenterol. 2017;112(8):1320-1329. [13] Kasper, D.L., Harrison ’ s gastroenterology and

hepatology. Third edition. ed. 2017, New York: McGraw-Hill

Education Medical. p. [14] Bynigeri RR, et al. Pancreatic stellate cell: Pandora’s box for pancreatic disease biology. World J Gastroenterol . 2017;23(3):382–405. [15] Hu F, Lou N, Jiao J, Guo F, Xiang H, Shang D. Macrophages in pancreatitis: Mechanisms and therapeutic potential. Biomed Pharmacother. 2020;131:110693. [16] Nomiyama Y, Tashiro M, Yamaguchi T, Watanabe S, Taguchi M, Asaumi H, Naka- mura H, Otsuki M: High glucose activates rat pancreatic stellate cells through protein

kinase C and p38 mitogen-activated protein kinase pathway. Pancreas 2007;3:364 –372 . [17] Capurso G, Archibugi L, Pasquali P, et al. Prevalence of chronic pancreatitis: Results of a primary care physician-based

population study. Dig Liver Dis. 2017;49(5):535-539. [18] Schrader H, Menge BA, Zeidler C, et al. Determinants of glucose control in patients with chronic pancreatitis. Diabetologia. 2010;53(6):1062-1069.

doi:10.1007/s00125-010-1705-0

[19] Rickels MR, Bellin M, Toledo FG, Robertson RP, AndersenDK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from

PancreasFest 2012. Pancreatology 2013; 13: 336-342. [20] International Diabetes Federation. IDF Diabetes Atlas, 10th ed. https://diabetesatlas.org/atlas/tenth-edition. Accessed

August 17, 2022. [21] American Diabetes Association. 2. Classification and

Diagnosis of Diabetes: Standards of Medical Care in Diabetes—

2021. Diabetes Care. 2021;44(suppl 1):S15-S33. [22] Lohr JM, et al. United European Gastroenterology

evidence- based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153–99. [23] Domínguez Muñoz JE. Diagnosis of chronic pancreatitis: functional testing. Best Pract Res Clin Gastroenterol. 2010;24(3):233–241. [24] Lévy P, Barthet M, Mollard BR, et al. Estimation ofthe prevalence and incidence of chronic pancreatitis and its complications. Gastroenterol Clin Biol. 2006;30(6–7):838–844. [25] Van de Vijver E, Desager K, Mulberg AE, et al. Treatment of infants and toddlers with cystic fibrosis-related

pancreatic insufficiency and fat malabsorption with pancrelipase MT.JPediatr Gastroenterol Nutr. 2011;53(1):61–64. [26] Creutzfeldt W, Gleichmann D, Otto J, Stock- mann F, Maisonneuve P, Lankisch PG: Fol- low-up of exocrine pancreatic function in type-1 diabetes mellitus. Digestion

2005;72: 71–75. [27] Koziel D, Gluszek S, Osuch MG. Course of acute pancreatitisin diabetic patients.Ann Ital Chir. 2016;87:18-22. [28] Liang.qi et al.Identification of Differential Metabolites Between Type 2 Diabetes and Postchronic Pancreatitis Diabetes

(Type 3c) Based on an Untargeted Metabolomics Approach.Lab

Med. 2023 Mar 2;lmad004. [29] Bhattamisra SK, Siang TC, Rong CY, et al. Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update. Curr Diabetes Rev. 2019;15(5):382-394. [30] Lee VTY, Poynten A, Depczynski B. Continuous glucose monitoring to assess glucose variability in type 3c diabetes

[published online ahead of print, 2022 May 15]. Diabet Med.

2022;e14882. [31] A. Tiengo, T. Segato, G. Briani et al.,“The presence of

retinopathy in patients with secondary diabetes following

pancreatec- tomy or chronic pancreatitis,”Diabetes Care, vol. 6, no. 6, pp. 570–574, 1983. [32] Briani, F. Riva, E. Midena et al.,“Prevalence of microangiopathic complications in hyperglycemia secondary to

pancreatic disease,”The Journal of Diabetic Complications, vol. 2, no. 1, pp. 50–52, 1988. [33] O. Ziegler, H. Candiloros, B. Guerci, I. Got, T. Crea,and P. Drouin,“Lower-extremity arterial disease in diabetes mellitus due to chronic pancreatitis,”Diabetes & Metabolism, vol. 20, no. 6, pp. 540–545, 1994. [34] Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of

hyper- glycemia in type 2 diabetes: a consensus algorithm for the

initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European As- sociation for

the Study of Diabetes. Diabetes Care 2009; 32: 193-203. [35] Rickels MR, Bellin M, Toledo FGS, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013;13(4):336–342. [36] Cefalu WT, Riddle MC. SGLT2 inhibitors: the latest “new kids on the block”! Diabete Care.2015;38(3):352–354. [37] Alves C, Batel-Marques F, Macedo AF . A meta-analysis of serious adverse events reported with exenatide

and li- raglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012; 98: 271-284.

[38] Andersen DK, Andren-Sandberg Å, Duell EJ, et al. Pancreatitis- diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas. 2013;42(8):1227– 1237. [39] Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic polypeptide administration

enhances insulin sensitivity and reduces the insulin requirement of

patients on insulin pump therapy. J Diabetes Sci Technol. 2011;5(6):1521– 1528. [40] Rickels MR, Bellin M, Toledo FGS, et al. Detection, evaluation and treatment of diabetes mellitusin chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013;13(4):336–342. [41] Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer- related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–258. [42] Rao GV, Pradeep R, Sasikala M, et al. Distal

pancreatectomy with autologous islet transplantation in chronic pancreatitis patients: Firstcase series from India. Indian J

Gastroenterol. 2018;37(5):452-456. [43] Rickels MR, Bellin M, Toledo FGS, et al. Detection, evaluation and treatment of diabetes mellitusin chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013;13(4):336–342. [44] Duggan SN, Conlon KC. A practical guide to the nutritional management of chronic pancreatitis. Pract Gastroenterol

2013; 118: 24–32.